APLI.TO实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 22:45):

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada...

Stats
今日成交量	3 000.00
平均成交量	192 619
市值	4.85M
EPS	$0 ( 2024-02-11 )
下一个收益日期	( $-0.0100 ) 2024-06-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.000
ATR14	$0 (0.00%)

APPILI THERAPEUTICS INC 相关性

10 最正相关
ISV.TO	0.832

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

APPILI THERAPEUTICS INC 财务报表

Annual	2022
营收:	$334 177
毛利润:	$327 911 (98.12 %)
EPS:	$-0.0813

FY	2022
营收:	$334 177
毛利润:	$327 911 (98.12 %)
EPS:	$-0.0813

FY	2022
营收:	$1.39M
毛利润:	$1.39M (100.00 %)
EPS:	$-0.380

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.240

Financial Reports:

No articles found.

APPILI THERAPEUTICS INC

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.